Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Pexip Q1 2022 – Key focus on accelerated return to profitability

Oslo, Norway, May 12, 2022 - The video communications provider, Pexip Holding ASA ("Pexip" or "The Company", Oslo Børs Ticker: PEXIP), today presented its quarterly results for the first quarter of 2022, showing revenue of NOK 222.5 million, a growth of 24 percent year-on-year and EBITDA margin of -23%, affected by the company’s significant investments in future growth.As previously communicated, Pexip is accelerating its return to positive financial results, and targets a return to positive EBITDA in Q4 2022 and for the full year 2023. Pexip’s new CEO, Trond K. Johannessen, took the reins

Bulletin from Ferronordic’s annual general meeting (AGM) 2022

At Ferronordic’s AGM on 12 May 2022, held without physical presence pursuant to the Act on temporary exceptions to facilitate the execution of general meetings in companies and other associations (SFS 2022:121), the shareholders resolved as follows:   · It was resolved not to pay dividends.   · The Company’s and the Group’s income statements and balance sheets were adopted.   · The Board members and CEO were discharged from liability for the financial year 2021.   · Annette Brodin Rampe, Lars Corneliusson, Håkan Eriksson and Staffan Jufors, Aurore Belfrage

Modus Therapeutics secures access to bridge financing from Karolinska Development

STOCKHOLM, SWEDEN - 12 May 2022: Modus Therapeutics Holding AB (“Modus”) announces that it has secured access to bridge financing of up to SEK 11.5 million from its largest shareholder, Karolinska Development. Access to this potential funding will ensure that momentum of clinical development of the company’s lead asset, sevuparin, for the treatment of sepsis is sustained. This includes the planning for the forthcoming Phase 2a study in patients with sepsis that is expected to begin before the end of 2022.John Öhd, CEO of Modus Therapeutics, said: “We are pleased to have secured access to

Transfer of Pihlajalinna Plc’s own shares

Pihlajalinna Plc                   Stock exchange release                          12 May 2022 at 5:15 p.m.  Transfer of Pihlajalinna Plc’s own shares Based on the decision of the General Meeting held on 13 April 2022, Pihlajalinna Plc has on 12 May 2022 transferred a total of 5,680 own shares possessed by the company to the members of the Board of Directors of Pihlajalinna as part of the Board’s renumeration. After the transfer, the company possesses 71,453 own shares. Pihlajalinna Plc’s General Meeting on 13 April 2022 decided that the Board’s annual remuneration will be

May 20 = International Clinical Trials Day THEME 2022: “RECRUITMENT IN CLINICAL TRIALS”

The BIG network:Recruiting patients globally for faster progress against breast cancer On May 20, which marks International Clinical Trials Day, the Breast International Group (BIG) wishes to shine some light on the importance of recruitment in clinical trials and how global research and collaboration can save lives.Thanks to its global network of breast cancer research groups, BIG can quickly enrol 1000s of patients from around the world into large clinical trials, leading to faster and stronger results and benefits for patients and healthcare systems.   So far, about 100,000

Report from Ambea’s annual shareholders’ meeting 12 May 2022

Today’s Annual General Meeting in Ambea AB (publ) voted to support all proposals from the board of directors and the nomination committee.The Annual General Meeting adopted the annual report for the financial year 2021 and resolved on a dividend of SEK 1.15 per share. Monday 16 May 2022 was established as record day for dividend. The dividend is expected to be paid out to the shareholders on Thursday 19 May 2022. The Annual General Meeting discharged the members of the board of directors and the CEO from liability for the financial year 2021. The Annual General Meeting resolved, in

Konecranes Plc - Managers' transactions - Juha Pankakoski

Konecranes Plc - Managers' transactions - Juha Pankakoski____________________________________________ Person subject to the notification requirementName: Pankakoski, JuhaPosition: Other senior managerIssuer: Konecranes PlcLEI: 549300EF0CDEQZBMA096 Notification type: INITIAL NOTIFICATIONReference number: 549300EF0CDEQZBMA096_20220512131743_273____________________________________________ Transaction date: 2022-05-11Venue: XHELInstrument type: SHAREISIN: FI0009005870Nature of the transaction: ACQUISITION Transaction details(1): Volume: 68 Unit price: 26.5996

Konecranes Plc - Managers' transactions - Mika Mahlberg

Konecranes Plc - Managers' transactions - Mika Mahlberg____________________________________________ Person subject to the notification requirementName: Mahlberg, MikaPosition: Other senior managerIssuer: Konecranes PlcLEI: 549300EF0CDEQZBMA096 Notification type: INITIAL NOTIFICATIONReference number: 549300EF0CDEQZBMA096_20220512131728_271____________________________________________ Transaction date: 2022-05-11Venue: XHELInstrument type: SHAREISIN: FI0009005870Nature of the transaction: ACQUISITION Transaction details(1): Volume: 34 Unit price: 26.5996 EUR

Konecranes Plc - Managers' transactions - Topi Tiitola

Konecranes Plc - Managers' transactions - Topi Tiitola____________________________________________ Person subject to the notification requirementName: Tiitola, TopiPosition: Other senior managerIssuer: Konecranes PlcLEI: 549300EF0CDEQZBMA096 Notification type: INITIAL NOTIFICATIONReference number: 549300EF0CDEQZBMA096_20220512131738_272____________________________________________ Transaction date: 2022-05-11Venue: XHELInstrument type: SHAREISIN: FI0009005870Nature of the transaction: ACQUISITION Transaction details(1): Volume: 56 Unit price: 26.5996 EUR

Spinnova Oyj: Managers' Transactions

SPINNOVA PLC, MANAGERS' TRANSACTIONS, 12 MAY 2022 at 4:15 p.m. EEST   Spinnova Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Besodos Investors Oy Position: Chief Executive Officer (X) Legal person   (1):Person Discharging Managerial Responsibilities In Issuer Name: Hanna Liiri Position: Member of the Board   Issuer: Spinnova Oyj LEI: 7437000SWC9YSSJWZB91 Notification type: INITIAL NOTIFICATION Reference number: 14691/11/16 _______________________________________

NetScientific PLC Preliminary Results for the year ended 31 December 2021

Good results demonstrate excellent progress in growth strategy to realise shareholder returns NetScientific plc (AIM: NSCI), the international life sciences and sustainability, technology investment and commercialisation group, announces its preliminary results for the year ended 31 December 2021. This was an excellent year of progress for the company as shown in the results. Implementation of its planned growth strategy  has accelerated and delivered a step change, both strategically and tactically.NetScientific plc (AIM: NSCI), the international life sciences and sustainability,

Advanced Drainage Systems joins the Cyclyx consortium

PORTSMOUTH, New Hampshire, USA, May 12, 2022 – Cyclyx International , a consortium-based post-use plastic innovation company with a mission to help increase the recyclability of plastic from 10% to 90%, announced that Advanced Drainage Systems, Inc. (ADS)  (NYSE:WMS) has joined the group.  ADS is a leading manufacturer of plastic stormwater management products, including drainage pipe which can be made with recycled content. Its products are used in the stormwater, sanitary sewer and on-site septic wastewater industries, providing superior

Saab Awarded Contract from US Army for Carl-Gustaf recoilless rifles

The U.S. Army MAAWS Program Office has awarded Saab a contract for Carl-Gustaf® M4 recoilless rifles. The Carl-Gustaf rifles are also known as Multi-purpose Anti-Armor Anti-personnel Weapon System (MAAWS) and M3A1 in the U.S. Army. The order will include deliveries of weapons for both the Army and the US Marine Corps. The contract has a total value of USD 16 million and is awarded under a current ID/IQ agreement.Saab will provide Carl-Gustaf recoilless rifles to continue supporting the ongoing fielding effort in both the Army and the Marine Corps.  “At Saab, we are always striving to

Starbreeze AB - Resolutions at Annual General Meeting 2022

Resolutions at Starbreeze’s Annual General Meeting 2022 STOCKHOLM, SWEDEN 12 May 2022 – At the Annual General Meeting (AGM) which was held today on 12 May 2022, the below principal resolutions were passed. For complete information about all resolutions at the AGM, please see the Company’s website www.starbreeze.com/investor-relations/corporate-governance/meetings-events. Annual accounts and discharge from liability The AGM adopted the consolidated income statement and consolidated balance sheet and granted the members of the Board of Directors and the CEO discharge from liability

Superyacht Industry Leaders Support Development of New ABS Rules

Advances in Safety, Sustainability and Flexible Design Discussed(COPENHAGEN) ABS brought together leading global yacht designers, shipyards and Flag Administrations to help develop new ABS rules to advance safety in superyacht and megayacht design and operation. Attendees at the inaugural ABS European Yacht Technical Meeting discussed the technology and innovation required by the yachts of the future, with a focus on flexible design compatible with emerging technologies. “Developing sustainable yachts that meet clients’ demand for greener yachts over long operational lives presents

BioStock: Emplicure’s co-founder on the company’s next step

Since it was founded in 2014, Emplicure has transformed from being a company with potential and ambitions of going public to today having one drug candidate heading into clinical studies and a consumer product ready to premiere in June. A person who has been involved throughout the company’s journey is co-founder Thomas Lundqvist, who resigned as chairman of the board in April. BioStock spoke to Lundqvist about his new role and how he sees the company’s future.Read the full article at biostock.se : https://www.biostock.se/en/2022/05/emplicures-medgrundare-om-

Magnolia Bostad announces final tender results and issues new senior unsecured green bonds of SEK 300 million

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND

Musti Group plc – Managers' transactions – Dettel

Musti Group plc – Managers' transactions – Dettel Musti Group plc            Managers’ transactions                  12 May 2022, at 3.30 p.m. Musti Group Oyj - Managers’ transactions                  ____________________________________________ Person subject to the notification requirement Name: Johan Dettel Position: Member of the Board/Deputy member Issuer: Musti Group LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL NOTIFICATION Reference number: 14841/4/4 ____________________________________________ Transaction date: 2022-05-11 Venue: NASDAQ

Invitation to presentation of Q1 2022 results

DOF ASA will release the Q1 results on Thursday 19th of May 2022. The report will be available at www.dof.com and www.newsweb.no. The presentation will be held as a webcast at 08:30 CET the same day on: http://www.dof.com/webcast. The presentation will be held by CEO Mons S. Aase and CFO Hilde Drønen.If you have questions, please contact the Company. Contact:CEO Mons Aase,     Tel + 47 91 66 10 12CFO Hilde Drønen, Tel + 47 91 66 10 09

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in HusCompagniet's shares

Company announcement 29/2022 Pursuant to the Market Abuse Regulation article 19, HusCompagniet A/S, CVR no. 36972963 ("HusCompagniet" or the “Company”), shall hereby notify receipt of information of the following transactions made by persons discharging managerial responsibilities in HusCompagniet and persons closely associated with them in HusCompagniet's shares and other financial instruments linked thereto. 1 Details of the Reporting Person and their Closely Associated Personsa) Name Stig Pastwa2 Reason for the notificationa)

BioStock: Sprint Bioscience maintains focus on developing the portfolio

With the activities for 2022 in full swing, Sprint Bioscience publishes the report for the year’s first quarter where we can note a continued focus on developing the programs in the portfolio. The company will begin presenting the latest internal program in the portfolio to potential partners and a scientific council has been appointed to support the future development. BioStock contacted the company’s CEO Erik Kinnman to get his thoughts on the first quarter.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/sprint-bioscience-maintains-focus-on-developing-the-

Communiqué from Annual General Meeting in BoMill AB

Idag, den 12 maj 2022, hölls årsstämma i BoMill AB (publ), 556556-4332. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Today, May 12, 2022, the Annual General Meeting of BoMill AB (publ), 556556-4332, was held. Below is a summary of the decisions made. All decisions were made by the required majority.Beslut om dispositioner beträffande bolagets resultat enligt den fastställda balansräkningen (punkt 8b) och ansvarsfrihet (punkt 8c) / Resolution regarding the allocation of the company’s results in accordance with the adopted

Getinge reaches record deliveries of vascular grafts to customers

After ramping up the production of polyester grafts and patches to treat aneurysmal and occlusive diseases, Getinge is now reaching delivery records, supporting health care staff around the world in the treatment of hundreds of patients per day with the help of these solutions. The demand for Getinge’s high quality vascular grafts is growing and following a 3 Million Euro investment in 2020 to increase manufacturing capacity at the Getinge La Ciotat (France) factory, the medtech supplier is reaching record months of deliveries to their customers. “Together with partners and

There are no items matching the current filter
There are no more items matching the current filter
Back to top